ImmunoGen Receives a Hold from Cowen & Co.

By Carrie Williams

Cowen & Co. analyst Boris Peaker reiterated a Hold rating on ImmunoGen (NASDAQ: IMGN) today. The company’s shares opened today at $7.58, close to its 52-week high of $8.04.

Peaker said:

“IMGN announced a collaboration agreement with Jazz for the development and.”

According to, Peaker is a 3-star analyst with an average return of 2.1% and a 40.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Iovance Biotherapeutics Inc, and Corvus Pharmaceuticals Inc.

Currently, the analyst consensus on ImmunoGen is Moderate Buy and the average price target is $10, representing a 31.9% upside.

In a report released today, Cantor Fitzgerald also reiterated a Hold rating on the stock.

The company has a one year high of $8.04 and a one year low of $1.51. Currently, ImmunoGen has an average volume of 3.06M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. Its product candidates include Mirvetuximab Soravtansine, Coltuximab ravtansine and Kadcyla . The company was founded in March 1981 and is headquartered in Waltham, MA.